keyword
MENU ▼
Read by QxMD icon Read
search

Drug induced dyskinesia

keyword
https://www.readbyqxmd.com/read/29115484/lipoic-acid-alleviates-l%C3%A2-dopa%C3%A2-induced-dyskinesia-in-6%C3%A2-ohda-parkinsonian-rats-via-anti%C3%A2-oxidative-stress
#1
Su-Fang Zhang, Cheng-Long Xie, Jing-Ya Lin, Mei-Hua Wang, Xi-Jin Wang, Zhen-Guo Liu
Levodopa (L‑DOPA) is the gold standard for symptomatic treatment of Parkinson's disease (PD); however, long‑term therapy is associated with the emergence of L‑DOPA‑induced dyskinesia (LID). Nigral dopaminergic cell loss determines the degree of drug exposure and time required for the initial onset of LID. Accumulating evidence indicates that α‑lipoic acid (ALA) decreases this nigral dopaminergic cell loss. However, until now, the precise mechanisms of ALA have only been partially understood in LID...
November 6, 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29114100/successful-treatment-of-severe-tardive-dyskinesia-with-valbenazine-including-a-patient-s-perspective
#2
Richard C Josiassen, Dawn M Filmyer, Jack Gillean, Syed Sikandar Shah, Tyler E Dietterich, Rita A Shaughnessy
BACKGROUND Tardive dyskinesia (TD) is a chronic involuntary movement disorder frequently induced by dopamine receptor blockers, particularly first-generation antipsychotics. Until recently, management of TD was restricted to lowering the dose of the current medication, switching to another medication, or using off-label treatments with insufficient evidence of efficacy. Valbenazine, a vesicular monoamine transporter-2 (VMAT2) inhibitor, became the first drug to be approved by the FDA specifically for the treatment of TD...
November 8, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29104832/belly-dancer-s-dyskinesia-a-glimpse-of-a-rare-phenomenon
#3
Ashutosh Gupta, Suman Kushwaha
Belly dancer's dyskinesia (BDD) is an extremely rare manifestation consisting of involuntary and repetitive rhythmic movements of the abdominal wall. These movements cannot be voluntarily suppressed but may be influenced by respiratory maneuvers. Investigations such as spinal cord and abdominal imaging usually fail to reveal any local abnormalities to explain the movement disorder. A 23-year-old male presented with sudden onset of undulating movements of the abdominal wall for the last two months after he took domperidone...
July 11, 2017: Curēus
https://www.readbyqxmd.com/read/29100803/the-effects-of-cysteamine-in-a-mouse-model-of-levodopa-induced-dyskinesias
#4
Linda S David, Martine Saint-Pierre, Jérôme Lamontagne-Proulx, Francesca Cicchetti
Levo-dopa (L-DOPA) has shown significant and long-lasting efficacy in the treatment of motor features characteristic of Parkinson's disease (PD). However, the effects tend to wear off at a time typically when side-effects, such as L-DOPA induced dyskinesias (LIDs), start to emerge and for which the treatment options are very limited. In recent years, we have reported on the neuroprotective and neurorestorative properties of the compounds cystamine/cysteamine in ameliorating several aspects of PD. Building on these observations, we set out to further evaluate the benefits of cysteamine on LIDs...
October 31, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/29076470/-unilateral-posteroventral-pallidotomy-in-the-treatment-of-drug-induced-dyskinesia-in-parkinson-s-disease
#5
V M Tyurnikov, D M Nizametdinova, A O Gushcha, E Yu Fedotova, V V Poleshchuk, S L Timerbaeva, A S Sedov
OBJECTIVE: to determine the efficacy of unilateral posteroventral pallidotomy (PVP) in the treatment of drug-induced dyskinesia (DID) in Parkinson's disease (PD). MATERIAL AND METHODS: We analyzed surgical treatment of 14 patients with PD complicated by DID who underwent unilateral PVP at the Research Center of Neurology in the period between 2012 and 2015. The clinical type of DID was mainly represented by peak-dose choreoathetoid dyskinesia, more pronounced in the distal limbs, and predominantly unilateral...
2017: Zhurnal Voprosy Neĭrokhirurgii Imeni N. N. Burdenko
https://www.readbyqxmd.com/read/29075830/presynaptic-dopamine-depletion-determines-the-timing-of-levodopa-induced-dyskinesia-onset-in-parkinson-s-disease
#6
Han Soo Yoo, Seok Jong Chung, Su Jin Chung, Hyojeong Moon, Jung Su Oh, Jae Seung Kim, Jin Yong Hong, Byoung Seok Ye, Young Ho Sohn, Phil Hyu Lee
PURPOSE: Reduced presynaptic dopaminergic activity plays an important role in the development of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). In this study, we investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of LID onset. METHODS: From among 412 drug-naive PD patients who underwent a dopamine transporter (DAT) PET scan during their baseline evaluation, we enrolled 65 patients who developed LID during a follow-up period of >2 years...
October 26, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29060621/automated-vision-based-analysis-of-levodopa-induced-dyskinesia-with-deep-learning
#7
Michael H Li, Tiago A Mestre, Susan H Fox, Babak Taati
Levodopa is the gold standard therapy for Parkinson's disease (PD), but its prolonged usage leads to additional motor complications, namely levodopa-induced dyskinesia (LID). To assess LID and adjust drug regimens for optimal relief, patients attend regular clinic visits. However, the intermittent nature of these visits can fail to capture important changes in a person's condition. With the recent emergence of deep learning achieving impressive results in a wide array of fields including computer vision, there is an opportunity for video analysis to be used for automated assessment of LID...
July 2017: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/29056747/prrt2-deficiency-induces-paroxysmal-kinesigenic-dyskinesia-by-regulating-synaptic-transmission-in-cerebellum
#8
Guo-He Tan, Yuan-Yuan Liu, Lu Wang, Kui Li, Ze-Qiang Zhang, Hong-Fu Li, Zhong-Fei Yang, Yang Li, Dan Li, Ming-Yue Wu, Chun-Lei Yu, Juan-Juan Long, Ren-Chao Chen, Li-Xi Li, Lu-Ping Yin, Ji-Wei Liu, Xue-Wen Cheng, Qi Shen, You-Sheng Shu, Kenji Sakimura, Lu-Jian Liao, Zhi-Ying Wu, Zhi-Qi Xiong
Mutations in the proline-rich transmembrane protein 2 (PRRT2) are associated with paroxysmal kinesigenic dyskinesia (PKD) and several other paroxysmal neurological diseases, but the PRRT2 function and pathogenic mechanisms remain largely obscure. Here we show that PRRT2 is a presynaptic protein that interacts with components of the SNARE complex and downregulates its formation. Loss-of-function mutant mice showed PKD-like phenotypes triggered by generalized seizures, hyperthermia, or optogenetic stimulation of the cerebellum...
October 20, 2017: Cell Research
https://www.readbyqxmd.com/read/29039022/metformin-inhibits-the-development-of-l-dopa-induced-dyskinesia-in-a-murine-model-of-parkinson-s-disease
#9
Young-Kyoung Ryu, Hye-Yeon Park, Jun Go, Dong-Hee Choi, Yong-Hoon Kim, Jung Hwan Hwang, Jung-Ran Noh, Tae Geol Lee, Chul-Ho Lee, Kyoung-Shim Kim
Metformin is a medication that is widely prescribed for the management of type 2 diabetes. In addition to its anti-diabetic uses, metformin has been proposed as a therapeutically effective drug candidate in various central nervous system disorders, including Parkinson's disease (PD). PD is characterized by severe movement defects and is commonly treated with the dopamine (DA) precursor 3,4-dihydroxyphenyl-l-alanine (L-DOPA). However, prolonged use of L-DOPA can lead to the development of L-DOPA-induced dyskinesia (LID)...
October 16, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28955204/impairment-of-serotonergic-transmission-by-the-antiparkinsonian-drug-l-dopa-mechanisms-and-clinical-implications
#10
REVIEW
Cristina Miguelez, Abdelhamid Benazzouz, Luisa Ugedo, Philippe De Deurwaerdère
The link between the anti-Parkinsonian drug L-3,4-dihydroxyphenylalanine (L-DOPA) and the serotonergic (5-HT) system has been long established and has received increased attention during the last decade. Most studies have focused on the fact that L-DOPA can be transformed into dopamine (DA) and released from 5-HT terminals, which is especially important for the management of L-DOPA-induced dyskinesia. In patients, treatment using L-DOPA also impacts 5-HT neurotransmission; however, few studies have investigated the mechanisms of this effect...
2017: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/28952832/prevalence-and-pattern-of-antipsychotic-induced-movement-disorders-in-a-tertiary-care-teaching-hospital-in-india-a-cross-sectional-study
#11
Nimisha Desai, Parvati B Patel, Sandip Shah, Tejas K Patel, Saurabh N Shah, Ela Vatsala
OBJECTIVES: To assess prevalence and pattern of movement disorders among patients taking antipsychotic medications. METHODS: This cross-sectional, intensive monitoring (patient interview, case record form review and clinical examination) study was conducted in patients taking antipsychotic drugs irrespective of duration for the development of movement disorders. The psychiatrist used Modified Simpson-Angus Scale score (10-item scale), Barnes' rating scale and Abnormal Involuntary Movement Scale to diagnose parkinsonism, akathisia and tardive dyskinesia, respectively...
September 27, 2017: International Journal of Psychiatry in Clinical Practice
https://www.readbyqxmd.com/read/28888928/an-update-on-new-and-unique-uses-of-botulinum-toxin-in-movement-disorders
#12
Joseph Jankovic
The therapeutic applications of botulinum toxin (BoNT) have grown manifold since its initial approval in 1989 by the US Food and Drug Administration (FDA) for the treatment of strabismus, blepharospasm, and other facial spasms. Although it is the most potent biologic toxin known to man, long-term studies have established its safety in the treatment of a variety of neurologic and non-neurologic disorders. This review focuses on some novel and uncommon uses of BoNT in the treatment of movement disorders, such as oromandibular dystonia, including bruxism, anterocollis, camptocormia, tremor, tics, tardive and levodopa-induced dyskinesia, and restless legs syndrome...
September 6, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28880414/levodopa-treatment-and-dendritic-spine-pathology
#13
REVIEW
Haruo Nishijima, Tatsuya Ueno, Yukihisa Funamizu, Shinya Ueno, Masahiko Tomiyama
Parkinson's disease (PD) is a neurodegenerative disorder associated with the progressive loss of nigrostriatal dopaminergic neurons. Levodopa is the most effective treatment for the motor symptoms of PD. However, chronic oral levodopa treatment can lead to various motor and nonmotor complications because of nonphysiological pulsatile dopaminergic stimulation in the brain. Examinations of autopsy cases with PD have revealed a decreased number of dendritic spines of striatal neurons. Animal models of PD have revealed altered density and morphology of dendritic spines of neurons in various brain regions after dopaminergic denervation or dopaminergic denervation plus levodopa treatment, indicating altered synaptic transmission...
September 7, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28854243/antiparkinsonian-effects-of-the-radiprodil-and-tozadenant-combination-in-mptp-treated-marmosets
#14
Anne Michel, Jean-Marie Nicolas, Sarah Rose, Michael Jackson, Peter Colman, Willy Briône, David Sciberras, Pierandrea Muglia, Dieter K Scheller, Martin Citron, Patrick Downey
OBJECTIVE: Investigate a combination of two clinically tested drugs, the NR2B antagonist Radiprodil and the A2A antagonist Tozadenant in the MPTP-treated marmoset model of Parkinson's Disease (PD). BACKGROUND: In PD, there remains a need for the development of non-dopaminergic drugs to effectively treat the motor symptoms without the induction of L-Dopa-induced motor complications. METHODS: Clinically relevant doses of Radiprodil and Tozadenant were given both alone and in combination without the addition of L-Dopa, and the antiparkinsonian efficacy of the treatments was assessed in a primate model of PD...
2017: PloS One
https://www.readbyqxmd.com/read/28836869/renin-angiotensin-system-as-a-potential-target-for-new-therapeutic-approaches-in-parkinson-s-disease
#15
REVIEW
Santiago Perez-Lloret, Matilde Otero-Losada, Jorge E Toblli, Francisco Capani
Currently, available therapies for Parkinson's disease (PD) are symptomatic. Therefore, the search for neuroprotective drugs remains a top priority. Areas covered: In this review, the potential symptomatic or disease-modifying effect of drugs targeting the Renin-Angiotensin System (RAS) in PD will be explored. Expert opinion: The importance of nigrostriatal local RAS has only begun to be unraveled in the last decades. On one hand, there is a complex feedback cycle between RAS and dopamine (DA). On the other hand, RAS affects dopaminergic neurons vulnerability...
October 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28833562/randomized-placebo-controlled-trial-of-ads-5102-amantadine-extended-release-capsules-for-levodopa-induced-dyskinesia-in-parkinson-s-disease-ease-lid-3
#16
Wolfgang Oertel, Karla Eggert, Rajesh Pahwa, Caroline M Tanner, Robert A Hauser, Claudia Trenkwalder, Reinhard Ehret, Jean Philippe Azulay, Stuart Isaacson, Larissa Felt, Mary Jean Stempien
BACKGROUND: The treatment of levodopa-induced dyskinesia in Parkinson's disease (PD) is an unmet need with no approved drug therapy. OBJECTIVE: The purpose of this study was to investigate the efficacy and safety of 274 mg ADS-5102 (amantadine) extended-release capsules (equivalent to 340-mg amantadine HCl) for levodopa-induced dyskinesia in a randomized controlled trial. METHODS: PD patients with ≥1 hour of troublesome dyskinesia and at least mild functional impact were randomized to placebo or ADS-5102 once daily at bedtime for 13 weeks...
August 21, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28812541/systematic-review-of-interventions-for-treating-or-preventing-antipsychotic-induced-tardive-dyskinesia
#17
Hanna Bergman, Dawn-Marie Walker, Adriani Nikolakopoulou, Karla Soares-Weiser, Clive E Adams
BACKGROUND: Antipsychotic medication can cause tardive dyskinesia (TD) - late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in > 20% of adults taking antipsychotic medication (first-generation antipsychotics for > 3 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses...
August 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28808283/drug-induced-extrapyramidal-symptoms-scale-diepss-serbian-language-version-inter-rater-and-test-retest-reliability
#18
Ami Peljto, Ljubica Zamurovic, Milica Pejovic Milovancevic, Branko Aleksic, Dusica Lecic Tosevski, Toshiya Inada
Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) is developed in the era of second-generation antipsychotics and is suitable for evaluation of the low incidence of extrapyramidal symptoms occurring in the treatment of atypical antipsychotics, as well as the relationship between personal and social functioning. The study was carried out at the Institute of Mental Health in Serbia in 2015 Study used the 127 DIEPSS video clips material, recorded from 1987 till 2015. Four raters performed the assessment simultaneously, individually rating one assigned item immediately after seeing the video clip...
August 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28757258/bdnf-over-expression-induces-striatal-serotonin-fiber-sprouting-and-increases-the-susceptibility-to-l-dopa-induced-dyskinesia-in-6-ohda-lesioned-rats
#19
Elisabetta Tronci, Francesco Napolitano, Ana Muñoz, Camino Fidalgo, Francesca Rossi, Anders Björklund, Alessandro Usiello, Manolo Carta
In addition to its role in neuronal survival, the brain neurotrophic factor (BDNF) has been shown to influence serotonin transmission and synaptic plasticity, events strongly implicated in the appearance of l-DOPA-induced dyskinesia (LID), a motor complication occurring in parkinsonian patients after long-term treatment with the dopamine precursor. In order to evaluate a possible influence of BDNF in the appearance of LID, 6-OHDA-lesioned rats received a striatal injection of different concentrations of an adeno-associated viral (AAV) vector over-expressing either BDNF or GFP, as control vector...
November 2017: Experimental Neurology
https://www.readbyqxmd.com/read/28751195/antinociceptive-antiallodynic-and-antihyperalgesic-effects-of-the-5-ht1a-receptor-selective-agonist-nlx-112-in-mouse-models-of-pain
#20
Kinga Sałat, Marcin Kołaczkowski, Anna Furgała, Adriana Rojek, Joanna Śniecikowska, Mark A Varney, Adrian Newman-Tancredi
BACKGROUND AND PURPOSE: NLX-112 (a.k.a. befiradol, F13640) is a drug candidate intended for the treatment of l-DOPA-induced dyskinesia. It is a highly selective serotonin 5-HT1A receptor full agonist which has been previously tested in a variety of models of CNS effects including analgesic activity in rat. Its activity in mouse models of pain has not been previously investigated. EXPERIMENTAL APPROACH: The activity of NLX-112 was tested in mouse models of acute pain (hot plate), tonic pain (intraplantar formalin test), in the oxaliplatin-induced neuropathic pain model of chemotherapy-induced peripheral neuropathy and in the streptozotocin (STZ)-induced model of painful diabetic neuropathy...
July 24, 2017: Neuropharmacology
keyword
keyword
120417
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"